Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 107,738 shares, a growth of 93.0% from the January 15th total of 55,812 shares. Based on an average daily volume of 2,264,204 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily volume of 2,264,204 shares, the days-to-cover ratio is currently 0.0 days.

Bayer Aktiengesellschaft Trading Down 1.0%

Shares of OTCMKTS BAYRY opened at $13.50 on Friday. Bayer Aktiengesellschaft has a 1-year low of $5.30 and a 1-year high of $13.98. The business has a fifty day moving average price of $11.80 and a 200 day moving average price of $9.39. The stock has a market capitalization of $53.06 billion, a P/E ratio of -149.98, a price-to-earnings-growth ratio of 4.89 and a beta of 0.68. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.14 and a quick ratio of 0.71.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on BAYRY. Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. JPMorgan Chase & Co. raised shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 20th. Finally, Barclays raised shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. Three analysts have rated the stock with a Strong Buy rating and four have given a Buy rating to the company. According to data from MarketBeat, Bayer Aktiengesellschaft has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.